Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Kinlay S, et al. Among authors: rifai n. Circulation. 2004 Jul 27;110(4):386-91. doi: 10.1161/01.CIR.0000136588.62638.5E. Epub 2004 Jul 19. Circulation. 2004. PMID: 15262833 Clinical Trial.
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Kinlay S, et al. Among authors: rifai n. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):142-7. doi: 10.1161/ATVBAHA.107.151787. Epub 2007 Nov 8. Arterioscler Thromb Vasc Biol. 2008. PMID: 17991875 Clinical Trial.
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators. Fraley AE, et al. Among authors: rifai n. J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96. doi: 10.1016/j.jacc.2009.02.041. J Am Coll Cardiol. 2009. PMID: 19497447 Free article. Clinical Trial.
Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia.
Kinlay S, Timms T, Clark M, Karam C, Bilodeau T, Ridker PM, Rifai N, Carlson W, Lloyd-Jones DM, Johnstone M, Rubenstein J, Alexander S, Orav J, Stone PH; Vascular Basis Study Group. Kinlay S, et al. Among authors: rifai n. Am J Cardiol. 2002 May 15;89(10):1205-7. doi: 10.1016/s0002-9149(02)02306-8. Am J Cardiol. 2002. PMID: 12008177 Clinical Trial. No abstract available.
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial.
Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, Stuehlinger M, Lin KY, Cooke JP, Morrow JD, Ridker PM, Rifai N, Miller E, Witztum JL, Mietus-Snyder M. Engler MM, et al. Among authors: rifai n. Circulation. 2003 Sep 2;108(9):1059-63. doi: 10.1161/01.CIR.0000086345.09861.A0. Epub 2003 Aug 11. Circulation. 2003. PMID: 12912807 Clinical Trial.
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. Kinlay S, et al. Among authors: rifai n. Circulation. 2003 Sep 30;108(13):1560-6. doi: 10.1161/01.CIR.0000091404.09558.AF. Epub 2003 Sep 15. Circulation. 2003. PMID: 12975259 Clinical Trial.
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Kinlay S, et al. Among authors: rifai n. Atherosclerosis. 2009 Oct;206(2):551-5. doi: 10.1016/j.atherosclerosis.2009.03.020. Epub 2009 Mar 26. Atherosclerosis. 2009. PMID: 19394618 Clinical Trial.
546 results